AxoGen Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- AxoGen's estimated annual revenue is currently $83.9M per year.
- AxoGen received $41.0M in venture funding in November 2017.
- AxoGen's estimated revenue per employee is $238,457
- AxoGen's total funding is $64.9M.
- AxoGen has 352 Employees.
- AxoGen grew their employee count by 33% last year.
- AxoGen currently has 33 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
What Is AxoGen?
It's time to rethink nerve repair! AxoGen (NASDAQ: AXGN) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. People suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. Damage may cause loss of function and feeling. AxoGen is bringing the science of nerve repair to life with its Avance® Nerve Graft which AxoGen believes is the first and only commercially available allograft for bridging nerve discontinuities, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector that protects nerves during the healing process.keywords:Biotechnology,E-Commerce,Healthcare,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
|David Hansen||Vice President, Finance And Treasurer|
|Karen Zaderej||President, Ceo And Chairman Of The Board|
|Jason Campbell||Regional Sales Director|
|Rich Epperly||Area Sales Manager|
|Matthew Stoy||Director, Business Intelligence & Commercial Operations|
|Matt Lawrence||Southeast Burn Account Manager|
|Kyle Brandt||Sales Area Manager||Email Available|
|Trent Pruitt||Area Sales Manager|
|Ryan Grant||Area Sales Manager|
|Devin Opdendyk||Professional Education Manager||Email Available|
Axogen is an elite partner for the meeting and will host a lunch symposium and panel discussion on Friday, September 6 from 12:00 – 1:00 p.m. ...
AxoGen, Inc (NASDAQ:AXGN) Director Quentin S. Blackford bought 15,535 shares of AxoGen stock in a transaction that occurred on Monday, ...
SAN DIEGO & ALACHUA, Fla.--(BUSINESS WIRE)--. Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of AxoGen, ...
AxoGen Executive Hires
|2011-01-13||Brad Hedger||VP Sales||Article|
|2012-02-14||Jill Schiaparelli||SVP Business Strategy/Marketing||Article|
|2013-03-06||Shawn McCarrey||VP Sales||Article|
|2014-05-13||Lee Robert Johnston||Chief Financial Officer||Article|
|2016-03-02||Peter J Mariani||CFO||Article|
|2017-01-06||Ivica Ducic||Medical Director of Clinical and Translational Sciences||Article|
|2017-07-18||Jon Gingrich||Chief Commercial Officer||Article|
|2018-09-05||Angelo Scopelianos||VP Research and Development||Article|
|2019-01-23||Eric Sandberg||Chief Commercial Officer||Article|
AxoGen New Location/Offices